Literature DB >> 16926145

Mylotarg is not a "magic bullet".

Ritsuro Suzuki, Kazuhiko Kobayashi, Naoko Murashige, Masahiro Kami.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16926145     DOI： 10.1532/IJH97.06073

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

1.  Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

Authors:  Richard A Larson; Eric L Sievers; Edward A Stadtmauer; Bob Löwenberg; Elihu H Estey; Hervé Dombret; Matthias Theobald; Dimitris Voliotis; John M Bennett; Maria Richie; Lance H Leopold; Mark S Berger; Matthew L Sherman; Michael R Loken; Jacques J M van Dongen; Irwin D Bernstein; Frederick R Appelbaum
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

2.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Authors:  P F Bross; J Beitz; G Chen; X H Chen; E Duffy; L Kieffer; S Roy; R Sridhara; A Rahman; G Williams; R Pazdur
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

3.  Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676).

Authors:  M C Petti; M B Pinazzi; D Diverio; A Romano; M T Petrucci; S De Santis; G Meloni; A Tafuri; F Mandelli; F Lo Coco
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

4.  Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

Authors:  K Naito; A Takeshita; K Shigeno; S Nakamura; S Fujisawa; K Shinjo; H Yoshida; K Ohnishi; M Mori; S Terakawa; R Ohno
Journal:  Leukemia       Date:  2000-08       Impact factor: 11.528

5.  Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.

Authors:  S Amadori; S Suciu; R Stasi; R Willemze; F Mandelli; D Selleslag; C Denzlinger; P Muus; R Stauder; Z Berneman; J Pruijt; F Nobile; V Cassibba; J-P Marie; F Beeldens; L Baila; M Vignetti; T de Witte
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

6.  Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent.

Authors:  Akihiro Takeshita; Kaori Shinjo; Kensuke Naito; Hirotaka Matsui; Naohi Sahara; Kazuyuki Shigeno; Taeko Suzumura; Toshinobu Horii; Naohito Shirai; Masato Maekawa; Yoshihiro Yada; Hirofumi Teshima; Jin Takeuchi; Kazunori Ohnishi; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

7.  Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically.

Authors:  N Zein; A M Sinha; W J McGahren; G A Ellestad
Journal:  Science       Date:  1988-05-27       Impact factor: 47.728

8.  A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

Authors:  William J Kell; Alan K Burnett; Raj Chopra; John A L Yin; Richard E Clark; Ama Rohatiner; Dominic Culligan; Ann Hunter; Archie G Prentice; Donald W Milligan
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

9.  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Giuseppe Cimino; Massimo Breccia; Nélida I Noguera; Daniela Diverio; Erica Finolezzi; Enrico M Pogliani; Eros Di Bona; Concetta Micalizzi; Mariagrazia Kropp; Adriano Venditti; Agostino Tafuri; Franco Mandelli
Journal:  Blood       Date:  2004-06-08       Impact factor: 22.113

10.  Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.

Authors:  I Jedema; R M Y Barge; V H J van der Velden; B A Nijmeijer; J J M van Dongen; R Willemze; J H F Falkenburg
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.